Managing the biopharmaceutical supply chain—who was doing it for BioNTech and Moderna jabs?

It's a legal requirement, but they don't seem to know

Are you getting it now?

Me thinks you are!

Subscribers to INSIDE PHARMA should be awake now to the crucial flaw in the Pfizer and Moderna jabs—they are biologics (living things) and the finished products were frozen down to temperatures so low (BioNTech -70 °C, Moderna -20 °C) that they could not be handled by the licensed wholesalers with the skills and expertise to distribute them.

This is an article published in Clinical Trials Arena in 2017 that explains the challenges of temperature sensitive supply chains for biologics and gene therapy: